FOR HEALTHCARE PROFESSIONALS

Patient Site  |  Important Safety Information  |  Referral Form 
About Treprostinil Injection   |   Cost Savings   |   Getting Started   |   Resources

Cost Savings

Discover How Treprostinil Injection Puts Control In Your Hands
Help shape the future costs of medication for your patients with Pulmonary Arterial Hypertension (PAH)

Today's PAH treatment options can carry a significant financial burden for patients

price icons
decrease in average monthly costs since launch2,3

Driving down costs with Sandoz® Treprostinil Injection

Sandoz Treprostinil Injection, for subcutaneous (SC) or intravenous (IV) use is a generic medicine that is therapeutically equivalent to the brand name medicine, Remodulin® (treprostinil) Injection.1

Since the launch of Treprostinil Injection, clinicians prescribing generic have decreased the average monthly out-of-pocket costs for Medicare Part B patients by ~$600 and decreased monthly costs allocated to CMS for Medicare Part B patients by ~$2,400.2,3

Why your choice matters

Medications such as Treprostinil Injection are reimbursed through Medicare Part B. Medicare Part B covers 80% of the calculated reimbursement rate for medications, leaving patients responsible for the remaining 20%.4

Brand name medications and their generic equivalents share a single billing code regardless of actual cost. Medicare Part B bases the reimbursement rate on the average selling price (ASP) and market share of each medication, plus a 6% markup to account for supply chain costs.5 Prescribing the higher cost medication may increase the financial burden patients may carry.

Chart Pie

Example: Cost Impact Scenarios6

Financial implications when two products (a brand and a generic) have the same billing code

Shifting the market toward generic can potentially provide significant savings

In this example there would be >$1000 in additional monthly savings to the patient and >$4000 in additional monthly savings to CMS

Cost table
  • Manufacturer ASP
  • Market Share
  • Shared J-Code ASP
  • Shared J-Code ASP +6%
  • CMS Cost Share = 80%
  • Patient Cost Share = 20%

It’s in your hands

By prescribing generics, such as Sandoz® Treprostinil Injection, in place of brand name medications, you can help patients and the healthcare system achieve significant savings.

The only thing generic about Sandoz® Treprostinil Injection is the price

  • The same specialty pharmacies that dispense, and provide patients with PAH-related support services, for brand Remodulin® (treprostinil) (Accredo)
  • Prescribers and clinics supported by Liquidia’s PAH experienced sales force
  • Trusted supply and quality provided by Sandoz
  • Available for intravenous (IV) and subcutaneous (SC) administration
Learn more about the the first fully substitutable generic for Remodulin® (treprostinil) Injection
References: 1. Treprostinil injection (prescribing information). Princeton, NJ: Sandoz Inc; April 2023. 2. Data on file. ASP Drug Pricing Files. 2019-2022. Sandoz Inc. 3. 2022 ASP Drug Pricing Files. Centers for Medicare & Medicaid Services. Accessed August 1, 2022. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files 4. Prescription drugs (outpatient). Medicare. gov website. https://www.medicare.gov/coverage/prescription-drugs-outpatient. Accessed August 1, 2022. 5. Medicare Part B Drug Average Sales Price. Accessed August 4, 2022. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice 6. Data on file: NVS ASP Trend, Dose Calculator, Cost Share Calculator. Sandoz Inc; 2022.



IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

•  Chronic intravenous (IV) infusions delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of bloodstream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
•  Do not abruptly lower the dose or withdraw dosing.
•  Treprostinil injection may cause symptomatic hypotension.
•  Titrate slowly in patients with hepatic insufficiency because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function.
•  Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding.

ADVERSE REACTIONS

During clinical trials with SC infusion of treprostinil, infusion site pain and infusion site reaction (e.g., erythema, induration, or rash) were the most common adverse events and occurred in majority of those treated with treprostinil. Infusion site reactions were sometimes severe and led to discontinuation of treatment. Rash and hypotension (14% and 4%, respectively) were also commonly reported with SC infusion of treprostinil. Other common adverse events (≥3% more than placebo) included headache, diarrhea, jaw pain, edema, vasodilatation, and nausea, and these are generally considered to be related to the pharmacologic effects of treprostinil, whether administered subcutaneously or intravenously. The adverse reactions reported with treprostinil IV included bloodstream infections, arm swelling, paresthesia, hematoma, and pain.

DRUG INTERACTIONS

Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

USE IN SPECIFIC POPULATIONS

•  Safety and effectiveness of Treprostinil injection in pediatric patients have not been established.
•  It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
•  There are no adequate and well-controlled studies with Treprostinil injection in pregnant women.
•  It is not known whether Treprostinil injection is excreted in human milk.

Please see accompanying full for additional safety information.

INDICATION

Treprostinil injection is a prostacyclin mimetic indicated for

•  Treatment of pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1 to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with New York Heart Association (NYHA) Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
•  Patients who require transition from epoprostenol to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

•  Chronic intravenous (IV) infusions delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of bloodstream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
•  Do not abruptly lower the dose or withdraw dosing.
•  Treprostinil injection may cause symptomatic hypotension.
•  Titrate slowly in patients with hepatic insufficiency because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function.
•  Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding.

ADVERSE REACTIONS

During clinical trials with SC infusion of treprostinil, infusion site pain and infusion site reaction (e.g., erythema, induration, or rash) were the most common adverse events and occurred in majority of those treated with treprostinil. Infusion site reactions were sometimes severe and led to discontinuation of treatment. Rash and hypotension (14% and 4%, respectively) were also commonly reported with SC infusion of treprostinil. Other common adverse events (≥3% more than placebo) included headache, diarrhea, jaw pain, edema, vasodilatation, and nausea, and these are generally considered to be related to the pharmacologic effects of treprostinil, whether administered subcutaneously or intravenously. The adverse reactions reported with treprostinil IV included bloodstream infections, arm swelling, paresthesia, hematoma, and pain.

DRUG INTERACTIONS

Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

USE IN SPECIFIC POPULATIONS

•  Safety and effectiveness of Treprostinil injection in pediatric patients have not been established.
•  It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
•  There are no adequate and well-controlled studies with Treprostinil injection in pregnant women.
•  It is not known whether Treprostinil injection is excreted in human milk.

Please see accompanying full for additional safety information.

INDICATION

Treprostinil injection is a prostacyclin mimetic indicated for

•  Treatment of pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1 to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with New York Heart Association (NYHA) Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
•  Patients who require transition from epoprostenol to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.